Home Newsfeeds Goldman Sachs Maintains Sell on Beyond Meat, Lowers Price Target to $5

Goldman Sachs Maintains Sell on Beyond Meat, Lowers Price Target to $5

Goldman Sachs analyst Adam Samuelson maintains Beyond Meat (NASDAQ:BYND) with a Sell and lowers the price target from $14 to $5.

byBenzinga Newsdesk

November 23, 2022

1 minute read

Goldman Sachs analyst Adam Samuelson maintains Beyond Meat (NASDAQ:BYND) with a Sell and lowers the price target from $14 to $5.

Rosenblatt Maintains Neutral on Sinclair Broadcast Group, Lowers Price Target to $18

By Benzinga Newsdesk

November 3, 7:43 AM

Rosenblatt analyst Barton Crockett maintains Sinclair Broadcast Group (NASDAQ:SBGI) with a Neutral and lowers the price target from $20 to $18.

SBGI

AMD, An Oil Fund At A Bargain, And A High-Flying Gold ETF On CNBC’s ‘Final Trades’

By Priya Nigam

May 9, 8:00 AM

On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners named Advanced Micro Devices, Inc. (NASDAQ: AMD), saying it’s "purely a trade, nothing more.&

AMD

Small Pharma’s IP Portfolio Grows With Numerous Approved Patent Applications Around The World

By Lara Goldstein

May 26, 11:30 AM

U.K.-based short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) has been working hard on securing a proprietary IP throughout North America, Australasia and Europe.

DMTTF

Lantern Pharma Announces Data Highlighting The Anti-Tumor Potency Of Drug Candidate LP-184 For Glioblastoma At The Society For Neuro-oncology Annual Meeting

By Benzinga Newsdesk

November 22, 9:08 AM

Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the

LTRN

Goldman Sachs Maintains Sell on Beyond Meat, Lowers Price Target to $5

Related Posts

Rosenblatt Maintains Neutral on Sinclair Broadcast Group, Lowers Price Target to $18

AMD, An Oil Fund At A Bargain, And A High-Flying Gold ETF On CNBC’s ‘Final Trades’

Small Pharma’s IP Portfolio Grows With Numerous Approved Patent Applications Around The World

Lantern Pharma Announces Data Highlighting The Anti-Tumor Potency Of Drug Candidate LP-184 For Glioblastoma At The Society For Neuro-oncology Annual Meeting